Compare · ALMR vs BRKR
ALMR vs BRKR
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $9.72B, about 6.7x ALMR ($1.45B).
- Over the past year, ALMR is down 5.7% and BRKR is up 65.8% - BRKR leads by 71.5 points.
- BRKR has been more active in the news (11 items in the past 4 weeks vs 6 for ALMR).
- BRKR has more recent analyst coverage (22 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Bruker Corporation
- Price
- $20.94+0.53%
- $62.69+9.29%
- Market cap
- $1.45B
- $9.72B
- 1M return
- -12.20%
- +72.25%
- 1Y return
- -5.65%
- +65.80%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- News (4w)
- 6
- 11
- Recent ratings
- 5
- 22
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest ALMR
- Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
- Leerink Partners initiated coverage on Alamar Biosciences with a new price target
- Stifel initiated coverage on Alamar Biosciences with a new price target
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports First Quarter 2026 Financial Results
- Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Latest BRKR
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)
- Bruker Corporation filed SEC Form 8-K: Other Events